Ariz. Admin. Code § 9-4-401

Current through Register Vol. 30, No. 50, December 13, 2024

Section R9-4-401 - Definitions

In this Article, unless otherwise specified:

.

1. "Analytic patient" means a patient, who is:

a. Diagnosed at a facility, or

b. Administered any part of a first course of treatment at the facility.

2. "Calendar year" means January 1 through December 31.

3. "Cancer" means a group of diseases characterized by uncontrolled cell growth and the spread of abnormal cells.

4. "Cancer registry" means a unit within a hospital or clinic that collects, stores, summarizes, distributes, and maintains information specified in R9-4-403 about patients who:

a. Are admitted to the hospital;

b. Receive diagnostic evaluation at, or cancer-directed treatment from, the hospital or clinic; or

c. Show evidence of cancer, carcinoma in situ, or a benign tumor of the central nervous system while receiving treatment from the hospital or clinic.

5. "Carcinoma" means a type of cancer that is characterized as a malignant tumor derived from epithelial tissue.

6. "Carcinoma in situ" means a cancer that is confined to epithelial tissue within the site of origin.

7. "Case report" means an electronic or paper document that includes the information in R9-4-403 for a patient.

8. "Chemotherapy" means the treatment of cancer using specific chemical agents or drugs that are selectively destructive to malignant cells and tissues.

9. "Clinic" means a facility that is not physically connected to or affiliated with a hospital, where a physician, doctor of naturo-pathic medicine, dentist, or registered nurse practitioner provides cancer diagnosis, cancer treatment, or both, and that is:

a. An outpatient treatment center, as defined in A.A.C. R9-10-101;

b. An outpatient surgical center, as defined in A.A.C. R9-10-101;

c. An outpatient radiation treatment center; or

d. A private office of one or more physicians, doctors of naturopathic medicine, dentists, or registered nurse practitioners that:

i. Is exempt from licensing under A.R.S. § 36-402(A)(3), and

ii. Treats 50 or more cancer patients per year.

10. "Clinical evaluation" means an examination of the body of an individual for the presence of disease or injury to the body, and review of any laboratory test results for the individual by a physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner.

11. "Clinical or pathological" means an analysis of evidence either acquired solely before a first course of treatment was initiated, or acquired both before a first course of treatment, and supplemented or modified by evidence acquired during and subsequent to surgery or other treatment.

12. "Cytology" means the microscopic examination of cells.

13. "Date of first contact" means the day, month, and year a reporting facility first began to provide cancer-related medical services, nursing services, or health-related services, as defined in A.R.S. § 36-401, to a patient.

14. "Date of last contact" means the day, month, and year that a reporting facility last knew a patient to be alive.

15. "Designee" means a person assigned by the governing authority, as defined in A.R.S. § 36-401, of a hospital or clinic or by an individual acting on behalf of the governing authority to gather information for or report to the Department, as specified in R9-4-403 or R9-4-404.

16. "Distant lymph node" means a lymph node that is not in the same general area of a human body as the primary site of a tumor.

17. "Distant site" means an area of a human body that is not adjacent to or in the same general area of the human body as the primary site of a tumor.

18. "Doctor of naturopathic medicine" means an individual licensed under A.R.S. Title 32, Chapter 14.

19. "First course of treatment" means the initial set of cancer- or non-cancer-directed treatment that is planned and administered to the patient when a cancer is diagnosed.

20. "Follow-up report" means an electronic document that includes the information stated in R9-4-404(A)(2) for a patient.

21. "Inpatient beds" means the same as in A.R.S. § 36-401.

22. "Licensed capacity" means the same as in A.R.S. § 36-401.

23. "Lymph" means the clear, watery, sometimes faintly yellowish fluid that circulates throughout the lymphatic system.

24. "Lymph node" means any of the small bodies located along lymphatic vessels, particularly at the neck, armpit, and groin, that filter bacteria and foreign particles from lymph.

25. "Lymphatic system" means the organ system that consists of lymph, lymph nodes, and vessels or channels that contain and convey lymph throughout a human body.

26. "Malignant" means an inherent tendency of a tumor to sequentially spread to areas of a human body beyond the site of origin.

27. "Medical record number" means a unique number assigned by a hospital, clinic, physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner to an individual for identification purposes.

28. "Melanocyte" means a skin cell that makes melanin, which is a dark pigment.

29. "Melanoma" means a dark-pigmented, malignant tumor arising from a melanocyte and occurring most commonly in the skin.

30. "Metastasis" means the spread of a cancer from a primary site into a regional site or a distant site.

31. "Narrative description" means a written text describing an act, occurrence, or course of events.

32. "Organ" means a somewhat independent part of a human body, such as a heart or a kidney, that performs a specific function.

33. "Organ system" means one or more organs and associated tissues that perform a specific function, such as the circulatory system.

34. "Outpatient radiation treatment center" means a facility regulated under 9 A.A.C. 7 that provides radiation treatment.

35. "Patient" means an individual who has been diagnosed with a cancer, carcinoma in situ, or benign tumor of the central nervous system:

a. Including melanoma; and

b. Excluding skin cancer that :

i. Is confined to the primary site, or

ii. Was diagnosed after January 1, 2003.

36. "Primary site" means a specific organ or organ system within a human body where the first cancer tumor originated.

37. "Principal diagnosis" means the primary condition for which an individual is admitted to a hospital or treated by the hospital.

38. "Radiation treatment" means the exposure of a human body to a stream of particles or electromagnetic waves for the purpose of selectively destroying certain cells or tissues.

39. "Reconstructive surgery" means a medical procedure that involves cutting into a body tissue or organ with instruments to repair damage or restore function to, or improve the shape and appearance of, a body structure that is missing, defective, damaged, or misshapen by cancer or cancer-directed therapies.

40. "Reference date" means the date on which the hospital's cancer registry began reporting patient information to the Department.

41. "Regional lymph node" means a lymph node that is in the same general area of a human body as the primary site of a tumor.

42. "Regional site" means an area of a human body that is adjacent to or in the same general area of the human body as the primary site of a tumor.

43. "Release" means to transfer care of a patient from a hospital to a physician, a doctor of naturopathic medicine, a registered nurse practitioner, an outpatient treatment center, another hospital, the patient, the patient's parent if the patient is under 18 years of age and unmarried, or the patient's legal guardian.

44. "Reporting facility" means a hospital, clinic, physician, doctor of naturopathic medicine, dentist, or registered nurse practitioner that submits a case report to the Department.

45. "Secondary diagnosis" means all other diagnoses of an individual that may be related to cancer made after the principal diagnosis.

46. "Skin cancer" means cancer of any of the following types:

a. Papillary tumor, a tumor of the skin producing finger-like projections from the skin surface;

b. Squamous cell, a flat, scale-like skin cell that forms part of the surface of the skin;

c. Basal cell, a cell of the inner-most layer of the skin; or

d. Other carcinoma of the skin, where a specific diagnosis has not been determined.

.

47. "Stage group" means a scheme for categorizing a patient, based on the staging classification of the patient's cancer, to enable a physician, doctor of naturopathic medicine, or registered nurse practitioner to provide better treatment and outcome information to the patient.

48. "Staging classification" means the categorizing of a cancer according to the size and spread of a tumor from its primary site, based on an analysis of three basic components:

a. The tumor at the primary site,

b. Regional lymph nodes, and

c. Metastasis.

49. "Tumor" means an abnormal growth of tissue resulting from uncontrolled multiplication of cells and serving no physiological function.

Ariz. Admin. Code § R9-4-401

Adopted effective January 1, 1992, filed September 25, 1991 (Supp. 91-3). Section repealed; new Section made by final rulemaking at 12 A.A.R. 179, effective March 11, 2006 (Supp. 06-1). Amended by final rulemaking at 3708, effective November 11, 2006 (Supp. 06-3). Amended by final rulemaking at 25 A.A.R. 3429, effective 1/1/2020.